ArticleOncology letters2025
Pan-cancer analysis reveals the potential role of DHCR24 in bladder cancer via interactions with HRAS to facilitate cholesterol synthesis.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- POU2F1 drives cholesterol biosynthesis and lipid remodeling through the DHCR24/ELOVL2 axis in endometrial cancer.Cancer & metabolism · 2026Article
- DHCR24 Drives Ovarian Cancer Chemoresistance Through Lipid Raft-mediated P-gp Stabilization and STAT3 Activation.International journal of biological sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is a strong association between cholesterol reprogramming and cancer development. However, 3β-hydroxysteroid Δ24-reductase (DHCR24), the final enzyme in the cholesterol biosynthesis pathway, has been relatively understudied in cancer progression. The present study aimed to perform a comprehensive pan-cancer analysis of DHCR24 to elucidate its role across different malignancies. The interacting proteins of DHCR24 were identified by molecular docking node dynamics simulation. Duolink proximity ligation, cell viability and filipin staining assays were used to assess the function of DHCR24 in cancer cells and its underlying oncogenic mechanisms. The findings revealed that DHCR24 exhibits high expression in seven cancer types (bladder cancer, breast invasive carcinoma, liver hepatocellular carcinoma, prostate adenocarcinoma, cervical squamous cell carcinoma and endocervical adenocarcinoma, uterine corpus endometrial carcinoma and stomach adenocarcinoma), and low expression in five others (glioblastoma multiforme, kidney chromophobe, kidney renal clear cell carcinoma, lung adenocarcinoma and lung squamous cell carcinoma), suggesting that DHCR24 serves distinct roles depending on the cancer type. Notably, it was demonstrated that DHCR24 expression consistently increases with tumor stage and serves as an independent prognostic factor in BLCA. Moreover, molecular docking and kinetic modeling identified HRAS as a key interacting protein of DHCR24. The Duolink assay further demonstrated that DHCR24 interacts with HRAS outside the nucleus in 5637 human BLCA cells. Filipin fluorescence staining and cell proliferation assays also revealed that this interaction promoted cholesterol synthesis, contributing to cancer cell proliferation in the 5637 cells. In conclusion, the results of the present study provide novel insights into the oncogenic role of DHCR24 in BLCA and demonstrates its interaction with HRAS for the first time to the best of our knowledge, highlighting a potential mechanism driving tumor progression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.